Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To define the mechanisms of action of 2 novel drugs, cyclosporine and anti-tumor necrosis factor alpha (TNFalpha), in collagen-induced arthritis and to determine the effect of combination therapy. METHODS: Type II collagen-immunized DBA/1 mice with established arthritis were treated with cyclosporine alone, anti-TNFalpha alone, cyclosporine plus anti-TNFalpha, or saline. RESULTS: Cyclosporine was found to ameliorate arthritis, suppress interferon-gamma (IFNgamma) production by CD4+ T cells, and reduce TNFalpha expression in arthritic joints. However, cyclosporine did not directly inhibit TNFalpha production by macrophages, indicating that the decrease in TNFalpha expression observed in vivo was probably an indirect consequence of the reduction in type 1 T helper cell activity. Anti-TNFalpha also reduced IFNgamma production by T cells, indicating that TNFalpha is involved in the cellular immune response to collagen. Combined treatment with cyclosporine plus anti-TNFalpha had an additive therapeutic effect. CONCLUSION: Although cyclosporine and anti-TNFalpha target different points in the inflammatory pathway, there is an overlap in the consequences of their actions in vivo.

Original publication

DOI

10.1002/1529-0131(199810)41:10<1806::aid-art12>3.0.co;2-9

Type

Journal article

Journal

Arthritis and rheumatism

Publication Date

10/1998

Volume

41

Pages

1806 - 1812

Addresses

Kennedy Institute of Rheumatology, London, UK.

Keywords

Th1 Cells, Animals, Mice, Inbred DBA, Mice, Arthritis, Experimental, Cyclosporine, Collagen, Tumor Necrosis Factor-alpha, Antibodies, Monoclonal, Drug Therapy, Combination, Dose-Response Relationship, Drug, Male